PCRX (Pacira BioSciences) Cyclically Adjusted Revenue per Share: $13.72 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCRX Pacira BioSciences Inc PCRX
69 GF Score
Price $24.43
GF Value $29.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences Cyclically Adjusted Revenue per Share?

Pacira BioSciences PCRX -2.36% 69 Cyclically Adjusted Revenue per Share is $13.72 as of Jun. 2026. GuruFocus rates PCRX with a GF Score™ of 69/100 and a GF Value™ of $29.11 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pacira BioSciences's adjusted revenue per share for the three months ended in Jun. 2026 was $4.774. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $13.72 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pacira BioSciences was 19.90% per year. The lowest was 7.20% per year. And the median was 12.75% per year.

As of today (2026-08-10), Pacira BioSciences's current stock price is $24.43. Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $13.72. Pacira BioSciences's Cyclically Adjusted PS Ratio of today is 1.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pacira BioSciences was 12.28. The lowest was 1.03. And the median was 4.32.


Pacira BioSciences  (NAS:PCRX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=24.43/13.72
=1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pacira BioSciences was 12.28. The lowest was 1.03. And the median was 4.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pacira BioSciences Cyclically Adjusted Revenue per Share Related Terms


Pacira BioSciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Cyclically Adjusted Revenue per Share Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.78 9.54 10.78 11.79 12.91

Pacira BioSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.43 12.72 12.91 13.35 13.72

PCRX vs ALVO, BIOA, COLL: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PS Ratio falls into.


PCRX
69GF Score
Pacira BioSciences Inc PCRX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.774/333.9520*333.9520
=4.774

Current CPI (Jun. 2026) = 333.9520.

Pacira BioSciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.832 241.428 2.534
201612 1.948 241.432 2.694
201703 1.823 243.801 2.497
201706 1.766 244.955 2.408
201709 1.664 246.819 2.251
201712 1.948 246.524 2.639
201803 1.833 249.554 2.453
201806 2.017 251.989 2.673
201809 2.036 252.439 2.693
201812 2.312 251.233 3.073
201903 2.214 254.202 2.909
201906 2.423 256.143 3.159
201909 2.514 256.759 3.270
201912 2.930 256.974 3.808
202003 2.470 258.115 3.196
202006 1.788 257.797 2.316
202009 2.654 260.280 3.405
202012 2.928 260.474 3.754
202103 2.589 264.877 3.264
202106 2.974 271.696 3.655
202109 2.809 274.310 3.420
202112 3.499 278.802 4.191
202203 3.402 287.504 3.952
202206 3.228 296.311 3.638
202209 3.654 296.808 4.111
202212 3.744 296.797 4.213
202303 3.490 301.836 3.861
202306 3.256 305.109 3.564
202309 3.148 307.789 3.416
202312 2.631 306.746 2.864
202403 3.202 312.332 3.424
202406 3.522 314.175 3.744
202409 3.654 315.301 3.870
202412 4.055 315.605 4.291
202503 3.631 319.799 3.792
202506 3.984 322.561 4.125
202509 4.038 324.800 4.152
202512 4.580 324.054 4.720
202603 4.336 330.213 4.385
202606 4.774 333.952 4.774

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $13.72 mean?
Pacira BioSciences (PCRX) has a Cyclically Adjusted Revenue per Share of $13.72 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Cyclically Adjusted Revenue per Share too high?
Pacira BioSciences' current Cyclically Adjusted Revenue per Share is $13.72. Overall, Pacira BioSciences has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cyclically Adjusted Revenue per Share compare to ALVO and BIOA?
Pacira BioSciences' Cyclically Adjusted Revenue per Share of $13.72 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Cyclically Adjusted Revenue per Share is $13.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.11, compared to a current price of $24.43 — trading 16.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $13.72. Pacira BioSciences' overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Cyclically Adjusted Revenue per Share is $13.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (PCRX) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of $24.43 is trading 16.1% below its estimated GF Value™ of $29.11. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for PCRX:

  • Cyclically Adjusted Revenue per Share: $13.72
  • GF Value™: $29.11 vs. price of $24.43 (16.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges 82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
69GF Score

Get the complete analysis for PCRX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.43
Price
$29.11
GF Value